<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854903</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000057</org_study_id>
    <nct_id>NCT03854903</nct_id>
  </id_info>
  <brief_title>WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor</brief_title>
  <official_title>A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, phase I trial. It is designed with a conservative dose&#xD;
      escalation plan to ensure patient's safety and with a strong translational component to&#xD;
      inform if target inhibition is achieved. With concerns regarding safety, based on extensive&#xD;
      available pharmacokinetic data and clinical efficacy experience, bosutinib will be given&#xD;
      5-days in a row followed by 2 days rest in a weekly basis, instead of daily.&#xD;
&#xD;
      The protocol will enroll patients per 3+3 escalation design. The Dose Limiting Toxicity (DLT)&#xD;
      observation period is 28 days. At the end of DLT observation period of each cohort of 3&#xD;
      patients, decision will be made regarding further escalation or de-escalation according to&#xD;
      this plan. Once the MTD of the combination is reached, the safety data will be analyzed.&#xD;
      There will be no dose reductions during DLT observation period. Dose reduction within&#xD;
      patients (individually) is allowed after the 4-week DLT observation period. Treatment in this&#xD;
      phase I trial will be administered until there is disease progression or unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity of adverse events will be measured via the Common Toxicity Criteria for Adverse Events (CTCAE 4.03)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of adverse events will be measured via the Common Toxicity Criteria for Adverse Events (CTCAE 4.03)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors</measure>
    <time_frame>1 year</time_frame>
    <description>Grade of adverse events will be measured via the Common Toxicity Criteria for Adverse Events (CTCAE 4.03)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Doses (MTD) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors</measure>
    <time_frame>28 days of therapy</time_frame>
    <description>This is a 3+3 escalation phase I study. Three patients will be enrolled at each dose cohort and an evaluation of dose escalation will take place after 3 patients have completed 28 days of therapy. If none of the 3 patients has a dose-limiting toxicity, the next cohort will be treated at the next dose level as per the dose escalation schema. At each dose level, if one patient experiences a dose-limiting toxicity, an additional 3 patients will be enrolled. If 2 or more patients experience dose-limiting toxicity in a single cohort (either 2/3 patients, or 2/6 patients in an expanded cohort), the MTD will have been exceeded and dose escalation will stop.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose (RP2D) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors</measure>
    <time_frame>1 year</time_frame>
    <description>Once the MTD of the combination is reached, the safety data will be analyzed. Dose reduction within patients (individually) is allowed after the 4-week DLT observation period. This phase I trial will inform the RP2D (recommended phase 2 doses of the drugs on the combination).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <condition>Hormone Receptor Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib: 75mg daily for 21 days of each 28 day cycle&#xD;
Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle&#xD;
Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib: 75mg daily for the first 21 days of each 28 day cycle&#xD;
Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib: 100mg daily for 21 days of each 28 day cycle&#xD;
Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle&#xD;
Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib: 100mg daily for 21 days of each 28 day cycle&#xD;
Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle&#xD;
Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib is taken orally.</description>
    <arm_group_label>Dose Level A1</arm_group_label>
    <arm_group_label>Dose Level A2</arm_group_label>
    <arm_group_label>Dose Level B1</arm_group_label>
    <arm_group_label>Dose Level B2</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>Bosutinib is taken orally.</description>
    <arm_group_label>Dose Level A1</arm_group_label>
    <arm_group_label>Dose Level A2</arm_group_label>
    <arm_group_label>Dose Level B1</arm_group_label>
    <arm_group_label>Dose Level B2</arm_group_label>
    <other_name>Bosulif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant is given as an intramuscular injection.</description>
    <arm_group_label>Dose Level A1</arm_group_label>
    <arm_group_label>Dose Level B1</arm_group_label>
    <arm_group_label>Dose Level B2</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent obtained prior to any study specific assessments and&#xD;
             procedures.&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Premenopausal and postmenopausal women&#xD;
&#xD;
          4. Biopsy proven diagnosis of ER and/or PR positive, HER2 negative, advanced breast&#xD;
             cancer (locoregionally recurrent or metastatic disease), either from the primary or a&#xD;
             metastatic site.&#xD;
&#xD;
             ER, PR and HER2 measurements should be performed according to institutional&#xD;
             guidelines, in a CLIA-approved setting.&#xD;
&#xD;
             Breast cancer is ER-positive and/or PR-positive tumor (≥1% positive stained cells)&#xD;
             based on local CLIA-certified laboratory results&#xD;
&#xD;
             HER2-negative breast cancer:&#xD;
&#xD;
             Cut-off values for positive/negative staining should be in accordance&#xD;
&#xD;
          5. A formalin-fixed paraffin-embedded (FFPE) tumor tissue block from diagnostic biopsy&#xD;
             must be transmitted to MedStar Georgetown University Hospital Pathology Department&#xD;
             repository and confirmation of receipt must be available prior to initiation of&#xD;
             treatment on study.&#xD;
&#xD;
          6. ECOG performance status 0-1&#xD;
&#xD;
          7. Must have received no more than 3 lines of chemotherapy for the treatment of breast&#xD;
             cancer and be progressive on at least one aromatase inhibitor and one CDK 4/6&#xD;
             inhibitor.&#xD;
&#xD;
          8. Pregnancy must be ruled out Serum or urine pregnancy test must be negative within 14&#xD;
             days of treatment start in women of childbearing potential.&#xD;
&#xD;
             Pregnancy testing does not need to be pursued in patients who are judged as&#xD;
             postmenopausal before enrollment, or who have undergone bilateral oophorectomy, total&#xD;
             hysterectomy, or bilateral tubal ligation.&#xD;
&#xD;
             Patients may be considered postmenopausal in case that one of the following criteria&#xD;
             applies (Section 5.4.1.2):&#xD;
&#xD;
             Prior bilateral oophorectomy, OR Age ≥ 60 years, OR Age &lt; 60 years with intact uterus&#xD;
             and amenorrhoeic for ≥ 12 consecutive months prior to chemotherapy and/or endocrine&#xD;
             therapy exposure, OR Age &lt; 60 years hysterectomized and FSH and plasma estradiol&#xD;
             levels in the post-menopausal range according to local policies prior to chemotherapy&#xD;
             and/or endocrine therapy exposure&#xD;
&#xD;
          9. Willingness to undergo adequate contraception if childbearing potential Women of&#xD;
             childbearing potential must use adequate contraception for the duration of protocol&#xD;
             treatment and for 3 months after the last treatment with palbociclib/bosutinib.&#xD;
&#xD;
             Adequate contraception is defined as one highly effective form (i.e. abstinence,&#xD;
             (fe)male sterilization) OR two effective forms (e.g. non-hormonal IUD and condom /&#xD;
             occlusive cap with spermicidal foam / gel / film / cream / suppository).&#xD;
&#xD;
         10. Patients must be able and willing to swallow and retain oral medication&#xD;
&#xD;
         11. Absolute neutrophil count (ANC) ≥ 1,500/mm^3&#xD;
&#xD;
         12. Platelets ≥ 100,000/mm^3&#xD;
&#xD;
         13. Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
         14. AST and/or ALT ≤3 x ULN&#xD;
&#xD;
         15. Alkaline phosphatase ≤2.5 x ULN (≤5.0 x ULN if bone metastases present)&#xD;
&#xD;
         16. Total serum bilirubin ≤1.5 x ULN&#xD;
&#xD;
         17. Serum creatinine within normal institutional limits or creatinine clearance ≥ 50&#xD;
             mL/min/1.73 m^2 for patients with serum creatinine levels above institutional ULN.&#xD;
&#xD;
         18. Resolution of all acute toxic effects of prior therapy, including radiotherapy to&#xD;
             grade ≤1 (except toxicities not considered a safety risk for the patient) and recovery&#xD;
             from surgical procedures.&#xD;
&#xD;
         19. Patients who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent therapy with other Investigational Products.&#xD;
&#xD;
          2. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4&#xD;
&#xD;
          3. Known hypersensitivity to fulvestrant, palbociclib or bosutinib, or to any of their&#xD;
             excipients.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness including (active infection, symptomatic congestive&#xD;
             heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, pulmonary&#xD;
             embolism in the past 6 months, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements).&#xD;
&#xD;
          5. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically&#xD;
             stable, as per Investigator's judgment, brain metastases are permitted.&#xD;
&#xD;
          6. Unable to comply with study requirements&#xD;
&#xD;
          7. Presence of a condition that would interfere with enteric absorption of&#xD;
             palbociclib/bosutinib.&#xD;
&#xD;
          8. Pregnant women, or women of childbearing potential without a negative pregnancy test&#xD;
             (serum or urine) within 14 days prior to starting treatment on study Breastfeeding&#xD;
             must be discontinued prior to study entry.&#xD;
&#xD;
          9. Patients on combination antiretroviral therapy, i.e. those who are HIV-positive&#xD;
             (potential for pharmacokinetic interactions or increased immunosuppression with&#xD;
             palbociclib).&#xD;
&#xD;
         10. Patients with clinically significant history of liver disease, including viral or&#xD;
             other known hepatitis, current alcohol abuse, or cirrhosis, etc.&#xD;
&#xD;
         11. Patients on chronic anticoagulation (fulvestrant is IM injection)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula R Pohlmann, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nellie Novielli, RN</last_name>
      <phone>202-687-3923</phone>
      <email>noviella@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Castle, RN</last_name>
      <phone>202-687-2209</phone>
      <email>bickmorj@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Pohlmann, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudine Isaacs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asma Dilawari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filipa Lynce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Warren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>HR+</keyword>
  <keyword>HER2-</keyword>
  <keyword>HR positive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>metastatic</keyword>
  <keyword>aromatase inhibitor</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <keyword>palbociclib</keyword>
  <keyword>bosutinib</keyword>
  <keyword>fulvestrant</keyword>
  <keyword>Faslodex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

